Cargando…

Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE()

Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis in HCC patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Divella, Rosa, Daniele, Antonella, Abbate, Ines, Savino, Eufemia, Casamassima, Porzia, Sciortino, Giancarlo, Simone, Giovanni, Gadaleta-Caldarola, Gennaro, Fazio, Vito, Gadaleta, Cosimo Damiano, Sabbà, Carlo, Mazzocca, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562977/
https://www.ncbi.nlm.nih.gov/pubmed/26310373
http://dx.doi.org/10.1016/j.tranon.2015.05.002
Descripción
Sumario:Although several molecular markers have been proposed as prognostic of disease progression in Hepatocellular carcinoma (HCC), predictive markers of response to treatment are still unsatisfactory. Here, we propose a genetic polymorphism as a potential predictive factor of poor prognosis in HCC patients treated with transcatheter arterial chemoembolization (TACE). In particular, we show that the guanosine insertion/deletion polymorphism in the promoter region of SERPINE1 gene at the − 675 bp position, named 4G/4G, predicts poor prognosis in a cohort of 75 patients with HCC undergoing TACE. By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE. Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE. In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.